Cereno Scientific Announces Presentation at Biotech Showcase™ 202010 January, 2020
Mölndal, Sweden – Cereno Scientific, a company developing preventive therapies to restore the body’s own defense system against blood clots to treat cardiovascular and rare diseases, announced today that Cereno’s Chief Executive Officer, Sten R. Sörensen, will present at Biotech Showcase™ 2020 being held January 13–15, 2020 at the Hilton San Francisco Union Square.
The details of Cereno’s presentation are as follows:
Date: Tuesday, January 14, 2020
Time: 9:30 AM
Room: Yosemite C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San
Francisco, CA (United States)
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
About Cereno Scientific AB
Cereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company’s lead program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientific also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation and high blood pressure in the pulmonary circulation system. Cereno Scientific also has two preclinical HDAC inhibitors, CS014 and CS036. The company is located in AstraZeneca’s BioVenture Hub. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.